Latest News & Features
Americas
A US presidential hopeful for the Democratic Party has urged the US to support a request that would permanently free poor countries from their responsibility to grant patent protection for drugs. 30 September 2015
Americas
Pharmaceutical company Allergan has survived an attempt by hedge fund Ferrum Ferro Capital to invalidate a patent covering its Combigan drug after the Patent Trial and Appeal Board opted not to institute an inter partes review. 29 September 2015
Asia-Pacific
A Japanese lawyer has described a ruling by the Supreme Court of Japan as a “death sentence” for product-by-process patents and said it is a good time for drugs companies to challenge rivals’ patents. 29 September 2015
Americas
Biopharmaceutical company Celgene has reiterated its stance on the inter partes review petitions filed by hedge fund manager Kyle Bass and has hinted it will appeal against a recent unfavourable decision. 29 September 2015
Americas
The US Patent and Trademark Office has rejected a request by biopharmaceutical company Celgene to sanction hedge fund manager Kyle Bass and his organisation the Coalition for Affordable Drugs. 28 September 2015
Americas
Concern surrounding how the Unified Patent Court will operate echoes the worry that US patent owners had ahead of the Patent Trial and Appeal Board’s implementation, a US law firm has observed. 28 September 2015
Big Pharma
A counsel for pharmaceutical company Novartis has said he “embraces” the Unified Patent Court, but has concerns about securing preliminary injunctions and the harmonisation of supplementary protection certificates under the agreement. 28 September 2015
Americas
A US appeals court has upheld a lower court ruling that patents owned by Shire covering an ADHD treatment drug are valid, but reversed a separate judgment that said pharmaceutical company Johnson Matthey induced infringement. 25 September 2015
Asia
An Indian court has granted pharmaceutical company Micro Labs permission to sue a rival, despite there being questions surrounding whether the suit should be heard at the court. 24 September 2015
Big Pharma
An advocate-general at Europe’s highest court has said SPCs should come into effect once an applicant for a marketing authorisation has been notified of that authorisation. This is good news for SPC owners, say Anja Lunze and Paul England of Taylor Wessing. 24 September 2015